Long-term safety of linagliptin monotherapy in Japanese patients with type 2 diabetes-Reference-Cited by-同舟云学术

Long-term safety of linagliptin monotherapy in Japanese patients with type 2 diabetes

Author:

Araki E.¹,Kawamori R.²,Inagaki N.³,Watada H.⁴,Hayashi N.⁵,Horie Y.⁶,Sarashina A.⁷,Thiemann S.⁸,von Eynatten M.⁸,Dugi K.⁸,Woerle H.-J.⁸

Affiliation:

1. Department of Metabolic Medicine; Kumamoto University Graduate School of Medicine; Kumamoto; Japan

2. Sportology Center; Juntendo University Graduate School of Medicine; Tokyo; Japan

3. Department of Diabetes and Clinical Nutrition; Kyoto University Graduate School of Medicine; Kyoto; Japan

4. Department of Metabolism and Endocrinology; Juntendo University Graduate School of Medicine; Tokyo; Japan

5. Clinical Research; Boehringer Ingelheim; Tokyo; Japan

6. Medical Data Service; Boehringer Ingelheim; Tokyo; Japan

7. Clinical Pharmacokinetics/Pharmacodynamics; Boehringer Ingelheim; Hyogo; Japan

8. Global Medical Affairs; Boehringer Ingelheim; Ingelheim; Germany

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

Reference25 articles.

1. Trends in the epidemiology of patients with diabetes in Japan;Morimoto;JMAJ,2010

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献